Last reviewed · How we verify
NCT03773718
Metabolic Syndrome in Childhood Cancer Survivors
trial in Metabolic Syndrome in 400 participants. Status unknown.
20 September 2021
Quick facts
| Lead sponsor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 20 November 2018 |
| Primary completion | 20 September 2021 |
| Estimated completion | 20 December 2022 |
| Sites | 1 location across Russia |
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Who can join
Adults 5 to 15, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The research is devoted to studying the features of the metabolic syndrome in cancer survivors in childhood is supposed to answer the following questions: * How can metabolic syndrome be diagnosed in the Russian population of survivors of acute lymphoblastic leukemia and non-Hodgkin's lymphomas? * What are the features of the clinical symptoms of metabolic syndrome in this category of patients? * Which genetic mutations are found in cancer survivors of patients with metabolic syndrome; Which of these mutations can be considered as protective or vice versa predisposing to the development of metabolic syndromes? Is the metabolic syndrome associated with an increased frequency of toxic complications of therapy during the intensive stages?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03773718
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Other Federal Research Institute of Pediatric Hematology, Oncology and Immunology trials
Trials by the same sponsor.
- NCT07316595 — Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome · Phase 2 · not yet recruiting
- NCT07375563 — Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Ris · Phase 3 · recruiting
- NCT07366801 — Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H · Phase 2, PHASE3 · recruiting
- NCT07232134 — The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia · Phase 3 · recruiting
- NCT06587191 — Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03773718 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Last refreshed: 20 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03773718.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing